65,437 trials
Androgenetic Alopecia · Hair Loss · Male Pattern Baldness
Primary: Changes in Terminal Hair Count at 16 and 26 Weeks Over Baseline — 17.7; 2.8; 18.4; 1.6 change in terminal hair count
Type 1 Diabetes
Primary: Maternal Confidence Scale — 38; 37 units on a scale — p=0.468
Tuberculosis
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t]) — 38.59; 38.81 microgram*hour/milliliter (mcg*h/mL)
Arthritis, Psoriatic, Psoriasis
Primary: Mean Cost Per Participant Per Month at Month 12 — 1026.32; 970.14; 4.14; 13.60 Euro/participant-month
Adherence · Depression · Heroin Dependence
Primary: Percent Medication Adherence at 3-month Follow-up Assessment — 79.02; 73.66 percent (doses taken/doses prescribed) — p=<.05
Renal Transplant
Primary: Incidence of Allograft Rejection — 13 participants
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR), Last Observation Carried Forward (LOCF) — 761.2; 731.6; 758.0; 703.6 dynes sec/cm^5
Chronic Renal Failure · Chronic Kidney Disease · Anemia
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.20; 11.21; 11.13; 11.05 g/dL
Chronic Renal Failure · Chronic Kidney Disease · Anemia
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.30; 11.32; 11.06; 11.25 g/dL
Chronic Renal Failure · Chronic Kidney Disease · Anemia
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 10.05; 9.95; 10.05; 11.47 g/dL
Chronic Renal Failure · Chronic Kidney Disease · Anemia
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 10.02; 10.03; 10.03; 11.55 g/dL
Hepatitis C, Chronic
Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 33; 104 participants — p=0.0064
Multiple Myeloma · Refractory Multiple Myeloma · Stage I Multiple Myeloma
Primary: Number of Patients Achieving 3 Million CD34 Cells/kg After 2 Days of Apheresis — 38 participants
Myopia · Dry Eye
Primary: Tear Osmolarity — 310; 313; 306 mOsms/L
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Salivary Gland Cancer
Primary: Number of Participants With Progression-free Survival at 12-weeks — 1 participants